Comparitive study on Virechana Karma and Basti Karma followed by Vidangadi Churna in the Management of lipid imbalance.

Phase 1/2

Not yet recruiting

Brief Summary: | |

| --- |

|I. **Null hypothesis [** *Virechana Karma* followed by *Vidangadi Churna and Basti Karma* followed by *Vidangadi Churna* are equally effective in the management of *Medoroga* w.s.r. to Dyslipidaemia..

**Alternative hypothesis [H1]:**

- *There is a difference between Virechana Karma* followed by *Vidangadi Churna* and *Basti Karma* followed by *Vidangadi Churna* in management of *Medoroga* w.s.r. to Dyslipidaemia.

Recruitment & Eligibility

Inclusion Criteria

corticosteroids,antidepressants,anticholinergics, immunosuppressant, oestrogen replacement therapy etc.
or any other drugs that may have an influence on the outcome of the study.
c)Symptomatic patient with clinical evidence of Heart failure.
d)Patients with poorly controlled hypertension (systolic >180 and diastolic >100 mm ofHg) e)Patients with evidence of malignancy.
f)Patients on oral contraceptives.
g)Alchohol and /or drug abusers.

Exclusion Criteria

a)Unstable angina: Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or severe Arrhythmia in the last six months.
b)Patients on prolonged (>6weeks) medication with corticosteroids,antidepressants,anticholinergics, immunosuppressant, oestrogen replacement therapy etc.
or any other drugs that may have an influence on the outcome of the study.
c)Symptomatic patient with clinical evidence of Heart failure.
d)Patients with poorly controlled hypertension (systolic >180 and diastolic >100 mm ofHg) e)Patients with evidence of malignancy.
f)Patients on oral contraceptives.
g)Alchohol and /or drug abusers.
h)Hypersensitivity to any of the trial drugs or their ingredients.
i)Patients who have completed participation in any other clinical trial drugs or theiringredients in one month period.
j)Patients who have received any cholesterol lowering medication (Modern Drug) within last two weeks.
k)Associated with any rectal pathology like haemorrhoids, fissure not fit for Virechanaand Basti Karma etc.
l)Pregnancy, Lactation and patients having Dyslipidaemia due to drugs e.g.Glucocorticoids, Diuretics etc.
m)Patients having Lipid Profile-Serum Cholesterol>400mg dl, Serum Triglycerides > 400mg/dl, LDL Cholesterol > 250 mg/dl,HDL Cholesterol < 20 mg/dl.

Primary Outcome Measures

Name	Time	Method
Changes in lipid profile	Changes in lipid profile - 45 days \| Change in BMI and BMI Prime. -45 days \| Change in anthropometric parameters -45 days
Change in BMI and BMI Prime.	Changes in lipid profile - 45 days \| Change in BMI and BMI Prime. -45 days \| Change in anthropometric parameters -45 days
Change in anthropometric parameters	Changes in lipid profile - 45 days \| Change in BMI and BMI Prime. -45 days \| Change in anthropometric parameters -45 days

Secondary Outcome Measures

Name	Time	Method
Reduction in Cardiac risk will be assessed by Framinghms 10 years cardiac risk score	After completion of trial 45 days

Locations (1): NIA Hospital Jaipur
🇮🇳
Jaipur, RAJASTHAN, India
NIA Hospital Jaipur
🇮🇳Jaipur, RAJASTHAN, India
Santvana Sharma
Principal investigator
9467632334
sharmasantvana@yahoo.in